AbbVie gets its first approval for a drug execs believe could be worth up to $5B in annual sales
AbbVie has tacked down its first regulatory approval for risankizumab as it begins what it hopes is a global rollout for the psoriasis drug in 2019 with a plan to quickly attain megablockbuster status.
Japan became the first country to stamp an OK on the drug, which has been dubbed Skyrizi for the marketing campaign. Evaluate has tagged this IL-23 drug as the number 3 blockbuster on its list of heavyweight drugs looking at a 2019 launch. They believe this drug could earn more than $2 billion in 2024.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.